To date, the evidence indicates the benefit of a fourth dose in the population over 50 years of age and with comorbidities. There are no recommendations by international regulatory agencies for the administration of fourth doses in populations outside the target population described. Recommendations for bivalent mRNA vaccines are expected to replace the formulations currently in use. However, they do not have regulatory approval.